Zhejiang Starry Pharmaceutical Co.,Ltd. (SHA:603520)

SHA:603520 Revenue

Zhejiang Starry Pharmaceutical had revenue of 711.27M CNY in the quarter ending March 31, 2026, with 3.70% growth. This brings the company's revenue in the last twelve months to 2.47B, up 3.23% year-over-year. In the year 2025, Zhejiang Starry Pharmaceutical had annual revenue of 2.45B with 4.07% growth.

• Revenue (ttm): 2.47B
• Revenue Growth: +3.23%
• P/S Ratio: 1.64
• Revenue / Employee: 1.30M
• Employees: 1,905
• Market Cap: 4.06B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	2.45B	95.55M	4.07%
Dec 31, 2024	2.35B	154.24M	7.02%
Dec 31, 2023	2.20B	64.75M	3.04%
Dec 31, 2022	2.13B	131.32M	6.57%
Dec 31, 2021	2.00B	632.83M	46.29%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 6, 2026

Data Sources Report a data error